Primary dysmenorrhea, menstrual cramping without an underlying condition like endometriosis or fibroids, affects a large share of menstruating people and is one of the most common reasons for missed school and work days. Standard options are NSAIDs and hormonal contraceptives, but between 10 and 25 percent of people with dysmenorrhea do not respond well to NSAIDs or cannot tolerate them, which is why a 2025 randomized controlled trial testing palmitoylethanolamide (PEA) for acute menstrual pain drew attention in the supplement research community.
This article covers what that trial actually measured, how large the effect was, and how it compares to the site’s existing coverage of PEA for other chronic pain conditions. As with everything on this site, PEA is a dietary supplement, not an FDA-approved treatment for dysmenorrhea, and severe or worsening pelvic pain should always be evaluated by a physician to rule out endometriosis, fibroids, or other causes of secondary dysmenorrhea.
Key Takeaways
- A 2025 randomized, double-blind, placebo-controlled crossover trial tested a single 300 mg dose of PEA (as Levagen+) taken at the onset of menstrual pain [1].
- PEA produced significantly lower pain scores than placebo at 1, 1.5, 2, and 2.5 hours after dosing, with the earliest and largest separation from placebo occurring in the first two hours.
- By 4 hours, pain relief was similar between groups, suggesting PEA’s advantage in this trial was faster onset and a lower pain trajectory in the acute window rather than a difference in eventual outcome.
- This was the first double-blind trial testing a single acute dose of PEA specifically for menstrual pain; prior PEA research focused on chronic daily dosing for other pain conditions.
- The trial was industry-supported by the ingredient’s supplier, which does not invalidate the results but is worth noting when weighing the evidence.
What the 2025 Menstrual Pain Trial Tested
The trial, published in the journal Women & Health in February 2025, used a randomized, double-blind, placebo-controlled crossover design conducted in Australia [1]. Participants took a single 300 mg dose of PEA or a matching placebo at the onset of menstrual pain, with a second dose permitted after two hours if pain persisted. Seventy-six participants recorded at least one qualifying pain event, and pain was tracked on a numerical rating scale every 30 minutes for up to four hours.
How Large Was the Effect
PEA produced statistically significant reductions in pain scores compared with placebo at 1 hour (p = .045), 1.5 hours (p = .009), 2 hours (p = .015), and 2.5 hours (p = .039) after dosing. Participants who took PEA showed at least a 25 percent greater reduction in recorded pain by the 2.5 hour mark compared with those on placebo. Adverse events were mild and roughly balanced between groups, with the PEA group reporting some lower back pain, brain fog, sleepiness, dry mouth, and increased menstrual bleeding, while the placebo group reported hot flushes, headache, and fatigue.
Why This Trial Is Different From PEA’s Other Pain Research
Most of the clinical evidence for PEA covered elsewhere on this site, in conditions like fibromyalgia, diabetic neuropathy, and chronic low back pain, involves daily dosing over weeks to months, since PEA’s proposed anti-inflammatory and mast-cell-stabilizing mechanism is generally understood to build gradually. The menstrual pain trial is notable because it tested a single acute dose taken at the onset of a pain episode, closer to how someone would use an over-the-counter pain reliever than how PEA is typically studied for chronic conditions. The researchers frame the proposed mechanism as PPAR-alpha activation dampening the inflammatory and prostaglandin-driven processes that drive menstrual cramping, a mechanism already discussed in more depth in this site’s article on how PEA works.
What the Study Doesn’t Tell Us
This was a single trial, and it specifically tested acute, event-triggered dosing rather than PEA taken preventively before a period starts. It also included participants using hormonal contraceptives, which can independently affect pain severity, so the results may not generalize evenly across all menstrual pain presentations. The trial did not compare PEA head to head against NSAIDs, so it cannot answer whether PEA is more or less effective than ibuprofen or naproxen for the same pain episode, only that it outperformed placebo. Anyone with pelvic pain that is severe, worsening over time, or accompanied by heavy bleeding, pain outside of menstruation, or pain during intercourse should see a physician, since these patterns can indicate endometriosis or other conditions that dysmenorrhea-focused supplement research does not address.
Practical Takeaways
The trial used a single 300 mg dose at the onset of pain, with a second dose allowed after two hours if needed, a pattern closer to as-needed use than the daily dosing schedules used in PEA’s chronic pain research. Micronized or ultramicronized PEA formulations are generally preferred across the clinical literature for better absorption, a distinction covered in more depth in this site’s article comparing PEA particle sizes. Anyone currently taking prescription medications should review potential interactions before adding PEA, covered in this site’s PEA drug interactions article.
Frequently Asked Questions
Does PEA work as fast as ibuprofen for menstrual cramps?
The 2025 trial showed PEA separating from placebo within an hour of dosing, but there is no head-to-head trial comparing PEA directly against NSAIDs like ibuprofen, so a direct speed comparison cannot be made from the available evidence.
How much PEA was used in the menstrual pain study?
The trial used a single 300 mg dose of PEA (as the branded ingredient Levagen+) taken at the onset of pain, with a second 300 mg dose permitted after two hours if pain continued.
Is PEA safe to take during a period?
The trial reported mild and roughly balanced adverse events between the PEA and placebo groups, including lower back pain, sleepiness, and dry mouth in the PEA group. As with any supplement, anyone with pre-existing conditions or taking other medications should discuss use with a physician first.
Can PEA replace a doctor’s evaluation for severe period pain?
No. Severe, worsening, or atypical pelvic pain should be evaluated by a physician to rule out endometriosis, fibroids, or other underlying causes, since the 2025 trial only studied PEA in the context of primary dysmenorrhea without those conditions.
References
- Rao A, et al. Palmitoylethanolamide (Levagen+) for acute menstrual pain: a randomized, crossover, double-blind, placebo-controlled trial. Women & Health (2025). PMID 39910730
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
